ALNYvsREGN
Alnylam Pharmaceuticals IncvsRegeneron Pharmaceuticals Inc. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.
Alnylam Pharmaceuticals Inc
$313.79
-19.78%
Regeneron Pharmaceuticals Inc
$766.02
+3.34%
60-day price, rebased to 100
Round-by-round
Valuation upside
-30.50% vs -22.60% to DCF fair value
Balance-sheet strength
Altman Z 5.77 vs 7.40
Fundamental quality
Piotroski 6.00 vs 5.00 (of 9)
Growth + margins
Rule-of-40 77.70 vs 27.20
60-day momentum
-7.18% vs +1.98% price return
Market-cap liquidity
$41.4B vs $79.2B
Verdict
Across6categories,REGNtakes the edge with4wins to2. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.
Backtest a strategy onALNYorREGN
Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.